$4 Target, page-122

But you show your real ignorance on this particular stock and its circumstances woth your commentary.

It has multibagged because it was (short term anyway) a binary play that got FDA approval for a drug that will bring this company hundreds of millions in revenue. This is just the pause while the market waits to get an idea of just how many hundreds of millions and in what timeframe.

Near term catalyst likely to destroy any shorter is a rest of world licensing deal for more hundreds of millions. A reasonable PE on these expected incomes sees us much much higher.

Then the market will also start looking at how close we are to getting Phasse II results for our next and even more exciting drug and its even larger markets. Feel free to short away but this is going way higher at some point and you'd best understand the risk if you're going to. We're just having a little resty here.